

CTI MOLECULAR IMAGING INC  
Form SC 13D/A  
April 29, 2005

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**AMENDMENT NO. 1 TO**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**CTI Molecular Imaging, Inc.**

---

(Name of Issuer)

**Common Stock, par value, \$0.01 per share**

---

(Title of Class of Securities)

**22943D105**

---

(CUSIP Number)

**Kenneth R. Meyers, Esq.**

**Siemens Corporation**

**153 East 53rd Street**

**New York, NY 10022**

**(212) 258-4797**

---

**(Name, address and telephone number of person authorized to receive notices and communications)**

**Copy to:**

**Stephen M. Besen, Esq.**

**Shearman & Sterling LLP**

**559 Lexington Ave**

**New York, NY 10022**

**(212) 848-8902**

**April 29, 2005**

---

**(Date of Event which Requires Filing of this Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See

§ 240.13d-7(b) for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**SCHEDULE 13D**

CUSIP No. 22943D105

1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

MI Merger Co.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

7  SOLE VOTING POWER

NUMBER OF 0

SHARES  8 SHARED VOTING POWER

BENEFICIALLY

OWNED BY 44,858,986

EACH  9 SOLE DISPOSITIVE POWER

REPORTING

PERSON 0

WITH  10 SHARED DISPOSITIVE POWER

44,858,986

Edgar Filing: CTI MOLECULAR IMAGING INC - Form SC 13D/A

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

44,858,986

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

92.4%

14 TYPE OF REPORTING PERSON (See Instructions)

CO

Page 2 of 9 Pages

**SCHEDULE 13D**

**CUSIP No.** 22943D105

1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

Siemens Medical Solutions USA, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

7  SOLE VOTING POWER

NUMBER OF 0

SHARES  8 SHARED VOTING POWER

BENEFICIALLY

OWNED BY 45,753,892

EACH  9 SOLE DISPOSITIVE POWER

REPORTING

PERSON 0

WITH  10 SHARED DISPOSITIVE POWER

45,753,892

Edgar Filing: CTI MOLECULAR IMAGING INC - Form SC 13D/A

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

45,753,892

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

94.2%

14 TYPE OF REPORTING PERSON (See Instructions)

CO

Page 3 of 9 Pages

**SCHEDULE 13D**

CUSIP No. 22943D105

1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

Siemens Aktiengesellschaft

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Federal Republic of Germany

7  SOLE VOTING POWER

NUMBER OF	0
SHARES	8 <input type="checkbox"/> SHARED VOTING POWER
BENEFICIALLY	
OWNED BY	45,753,892
EACH	9 <input type="checkbox"/> SOLE DISPOSITIVE POWER
REPORTING	
PERSON	0
WITH	10 <input type="checkbox"/> SHARED DISPOSITIVE POWER

45,753,892

Edgar Filing: CTI MOLECULAR IMAGING INC - Form SC 13D/A

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

45,753,892

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

94.2%

14 TYPE OF REPORTING PERSON (See Instructions)

CO

Page 4 of 9 Pages



This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D (as amended and supplemented, the Statement ) originally filed on March 28, 2005, by MI Merger Co., a Delaware corporation ( Purchaser ) and a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., a Delaware corporation ( Parent ) and an indirect wholly owned subsidiary of Siemens Aktiengesellschaft, a corporation organized under the laws of the Federal Republic of Germany ( Siemens AG ), in connection with the offer by Purchaser to purchase all the common stock, par value \$0.01 per share, including the associated preferred stock purchase rights (together, the Shares ) of CTI Molecular Imaging, Inc., a Delaware corporation (the Issuer or the Company ) pursuant to the Purchaser s Offer to Purchase (the Offer to Purchase ). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Statement.

Capitalized terms not otherwise defined herein shall have the meanings assigned to them in the Statement.

#### Item 5. Interest in Securities of the Issuer

Item 5 is amended and supplemented to include the following:

(a)-(b) At 12:00 midnight, New York City time, on Thursday, April 28, 2005, the Offer expired. Based on information provided by the Depository, as of such time, 39,088,810 Shares were tendered pursuant to the Offer, representing approximately 80% of the outstanding Shares based upon 48,557,021 outstanding Shares as reported to Purchaser by the Company on April 28, 2005. In addition, 5,770,176 shares, representing approximately 12% of the outstanding Shares, were tendered subject to guaranteed delivery. All Shares validly tendered and not withdrawn prior to the expiration of the Offer were accepted for payment in accordance with the terms of the Offer. The aggregate number of Shares tendered is 44,858,986, which is the number of Shares beneficially owned by Purchaser, and constitutes approximately 92.4% of the outstanding Shares. Such Shares, together with the Shares already beneficially owned by Parent and Siemens AG number 45,753,892, which is the number of Shares beneficially owned by Parent and Siemens AG, and constitutes approximately 94.2% of the outstanding Shares.

(c)-(d) Except as described herein, neither the Reporting Persons nor, to the best of its knowledge, any of the executive officers or directors of the Reporting Persons, has acquired or disposed of any Shares during the past 60 days. Furthermore, the Reporting Persons do not know of any other person with the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities covered by this Statement.

<u>Exhibit No.</u>	<u>Description</u>
1.	Joint Filing Agreement, dated March 28, 2005, among Siemens Aktiengesellschaft, Siemens Medical Solutions USA, Inc. and MI Merger Co.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:

April 29, 2005

SIEMENS AKTIENGESELLSCHAFT

/s/ Robert Kirschbaum

---

Signature

Robert Kirschbaum/Syndikus

---

Name/Title

SIEMENS MEDICAL SOLUTIONS USA, INC.

/s/ Dr. James Ruger

---

Signature

Dr. James Ruger/Secretary

---

Name/Title

MI MERGER CO.

/s/ Kenneth R. Meyers

---

Signature

Kenneth R. Meyers/Secretary

---

Name/Title

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
1.	Joint Filing Agreement, dated April 29, 2005, among Siemens Aktiengesellschaft, Siemens Medical Solutions USA, Inc. and MI Merger Co.

Page 7 of 9 Pages